Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4212549 | 0.95 | FAP (0.72) | FAPCYP3A4CYP2D6 | |
| SCHEMBL969657 | 0.89 | FAP (0.69) | FAPCYP3A4CYP2D6 | |
| SCHEMBL28395512 | 0.87 | FAP (0.85) | FAPCYP3A4CYP2D6 | |
| SCHEMBL29402746 | 0.87 | FAP (0.85) | FAPCYP3A4CYP2D6 | |
| SCHEMBL14507066 | 0.87 | FAP (0.85) | FAPCYP3A4CYP2D6 | |
| Fumaric Acid SCHEMBL2670558 | 0.85 | FAP (0.71) | FAPCYP3A4CYP2D6 | |
| Fumaric Acid SCHEMBL28393645 | 0.84 | FAP (0.70) | FAPCYP3A4CYP2D6 | |
| Fumaric Acid SCHEMBL29389347 | 0.84 | FAP (0.70) | FAPCYP3A4CYP2D6 | |
| SCHEMBL24809662 | 0.83 | CYP3A4 (0.80) | FAPCYP3A4CYP2D6 | |
| SCHEMBL14440381 | 0.83 | CYP3A4 (0.80) | FAPCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150366795-A1 | TOPICAL ANTIVIRAL FORMULATIONS | GILEAD SCIENCES, INC. | 2015-12-24 | — | — | US | claimed |
| EP-2138162-A2 | GEL COMPRISING TENOFOVIR OR TENOFOVIR DISOPROXIL | Gilead Sciences, Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| EP-2138163-A2 | SUPPOSITORY FORMULATIONS COMPRISING TENOFOVIR OR TENOFOVIR DISOPROXIL | GILEAD SCIENCES, INC. (US) | 2009-12-30 | — | — | EP | claimed |
| US-20080035155-A1 | Topical Antiviral Formulations | GILEAD SCIENCES, INC. (US) | 2008-02-14 | — | — | US | claimed |
| US-20060058265-A1 | Topical antiviral formulations | GILEAD SCIENCES, INC. | 2006-03-16 | — | — | US | claimed |
| CN-110372750-B | Synthesis method of tenofovir disoproxil fumarate impurity | 苏利制药科技江阴有限公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20170273994-A1 | Compositions and Methods for Combination Antiviral Therapy | GILEAD SCIENCES, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170273994-A1 | Compositions and Methods for Combination Antiviral Therapy | GILEAD SCIENCES, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9744181-B2 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744181-B2 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170232019-A1 | Compositions and Methods for Combination Antiviral Therapy | GILEAD SCIENCES INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170232019-A1 | Compositions and Methods for Combination Antiviral Therapy | GILEAD SCIENCES INC (US) | 2017-08-17 | — | — | US | disclosed |
| CN-1738628-A | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES INC (US) | 2006-02-22 | — | — | CN | disclosed |
| EP-1583542-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050197320-A1 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. | 2005-09-08 | — | — | US | disclosed |
| US-20040224916-A1 | Administering combination comprising 9-[R-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) or a physiologically functional derivative thereof, and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | disclosed |
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | disclosed |
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | disclosed |
| WO-2004064845-A8 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES INC (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004064845-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224916-A1 | Administering combination comprising 9-[R-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) or a physiologically functional derivative thereof, and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | MTAP, TYMP, TYMS | FAP 1649/4885CYP3A4 337/4885CYP2D6 1163/4885 |
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | DCTD, MTAP, TYMP | FAP 291/4885CYP3A4 471/4885CYP2D6 545/4885 |
| US-20060058265-A1 | Topical antiviral formulations | PNP, TYMP, NT5C2 | FAP 1035/4885CYP3A4 2475/4885CYP2D6 737/4885 |
| US-20170273994-A1 | Compositions and Methods for Combination Antiviral Therapy | DCTD, TYMP, MTAP | FAP 422/4885CYP3A4 213/4885CYP2D6 233/4885 |
| US-20150366795-A1 | TOPICAL ANTIVIRAL FORMULATIONS | PNP, TYMP, NT5C2 | FAP 1035/4885CYP3A4 2475/4885CYP2D6 737/4885 |
| US-20080035155-A1 | Topical Antiviral Formulations | PNP, TYMP, TK1 | FAP 1151/4885CYP3A4 3344/4885CYP2D6 1239/4885 |
| US-20170232019-A1 | Compositions and Methods for Combination Antiviral Therapy | DCTD, TYMP, MTAP | FAP 422/4885CYP3A4 213/4885CYP2D6 233/4885 |
| US-20050197320-A1 | Non nucleoside reverse transcriptase inhibitors | TYMP, PNP, ITPA | FAP 365/4885CYP3A4 2125/4885CYP2D6 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.